Literature DB >> 3035936

Epinephrine increases plasma immunoreactive atrial natriuretic hormone levels in humans.

J A Sanfield, Y Shenker, R J Grekin, S G Rosen.   

Abstract

Six normal human subjects each underwent sequential 80-min infusions of saline and epinephrine (EPI) at 0.55 and 2.75 micrograms X min-1 X m-2 to determine the role of EPI in the control of atrial natriuretic hormone (ANH) in humans. Plasma immunoreactive-ANH (IR-ANH) levels nearly doubled in response to the infusion of EPI at 0.55 microgram X min-1 X m-2 (P less than 0.05) and then plateaued; heart rate accelerated significantly (P less than 0.01) with increasing plasma EPI levels, whereas systolic blood pressure increased only with higher plasma EPI levels (P less than 0.05). To determine whether beta-adrenergic mechanisms mediate the EPI-induced increase in IR-ANH, six additional subjects each received infusions on two separate days of saline for 240 min and the beta-adrenergic antagonist propranolol followed by propranolol plus EPI at 2.75 micrograms X min-1 X min-2 each for 80 min. Neither saline nor propranolol plus EPI caused a significant increase in plasma IR-ANH. We conclude that EPI increases plasma IR-ANH through beta-adrenergic mechanisms in humans. beta-Adrenergic-mediated increases in plasma IR-ANH levels appear to be unrelated to changes in the heart rate.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3035936     DOI: 10.1152/ajpendo.1987.252.6.E740

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  12 in total

1.  Responsiveness of the ANP providing system to volume load in conscious dogs.

Authors:  Y Nishida; A Miyata; H Morita; N Uemura; K Kangawa; H Matsuo; H Hosomi
Journal:  Pflugers Arch       Date:  1988-10       Impact factor: 3.657

Review 2.  Effects of exercise on atrial natriuretic factor. Release mechanisms and implications for fluid homeostasis.

Authors:  B J Freund; C E Wade; J R Claybaugh
Journal:  Sports Med       Date:  1988-12       Impact factor: 11.136

3.  Atrial natriuretic peptide in plasma after prolonged physical strain, energy deficiency and sleep deprivation.

Authors:  P K Opstad; A H Haugen; O M Sejersted; R Bahr; K K Skrede
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1994

4.  Influence of endogenous opioids on atrial natriuretic factor release during exercise in man.

Authors:  F Louisy; C Y Guezennec; M Lartigue; J C Aldigier; F X Galen
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1989

5.  Disinhibition of AVP release during noradrenaline and angiotensin II infusions in dogs by maintaining normotension with sodium nitroprusside.

Authors:  M Szczypaczewska; E Simon; C Simon-Oppermann; D A Gray
Journal:  Pflugers Arch       Date:  1993-05       Impact factor: 3.657

6.  Effect of beta-adrenoceptor blockade on atrial natriuretic peptide levels during exercise in angina pectoris.

Authors:  M Riley; J S Elborn; G Onuoha; C Erwin; C Shaw; M M Khan; C F Stanford; D P Nicholls
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

7.  Increased release of alpha-atrial natriuretic peptide during controlled mechanical ventilation with positive end-expiratory pressure in humans.

Authors:  T Sata; J Yoshitake
Journal:  J Anesth       Date:  1988-09-01       Impact factor: 2.078

8.  Elevation of plasma atrial natriuretic peptide occurs during adrenaline infusion in hypertensive but not normotensive subjects.

Authors:  T J Tunny; R D Gordon; A W Bachmann; S A Klemm
Journal:  Clin Auton Res       Date:  1992-10       Impact factor: 4.435

9.  Effects of physical exercise and anti-G suit inflation on atrial natriuretic factor plasma level.

Authors:  C Y Guezennec; E Fournier; F X Galen; M Lartigues; F Louisy; J Gutkowska
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1989

10.  Atrial natriuretic factor in chronic obstructive lung disease with pulmonary hypertension. Physiological correlates and response to peptide infusion.

Authors:  S Adnot; P Andrivet; P E Chabrier; J Piquet; P Plas; P Braquet; F Roudot-Thoraval; C Brun-Buisson
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.